BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 30740964)

  • 1. Six months response rate of combined oral medroxyprogesterone/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women: a Korean Gynecologic-Oncology Group Study.
    Kim MK; Seong SJ; Kang SB; Bae DS; Kim JW; Nam JH; Lim MC; Lee TS; Kim S; Paek J
    J Gynecol Oncol; 2019 Mar; 30(2):e47. PubMed ID: 30740964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dilatation and curettage is more accurate than endometrial aspiration biopsy in early-stage endometrial cancer patients treated with high dose oral progestin and levonorgestrel intrauterine system.
    Kim DH; Seong SJ; Kim MK; Bae HS; Kim M; Yun BS; Jung YW; Shim JY
    J Gynecol Oncol; 2017 Jan; 28(1):e1. PubMed ID: 27670255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer.
    Kim MK; Seong SJ; Song T; Kim ML; Yoon BS; Jun HS; Lee GH; Lee YH
    Gynecol Oncol; 2013 Sep; 130(3):470-3. PubMed ID: 23822890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer.
    Kim MK; Seong SJ; Kim YS; Song T; Kim ML; Yoon BS; Jun HS; Lee YH
    Am J Obstet Gynecol; 2013 Oct; 209(4):358.e1-4. PubMed ID: 23791687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Oral Medroxyprogesterone/Levonorgestrel-Intrauterine System Treatment for Women With Grade 2 Stage IA Endometrial Cancer.
    Hwang JY; Kim DH; Bae HS; Kim ML; Jung YW; Yun BS; Seong SJ; Shin E; Kim MK
    Int J Gynecol Cancer; 2017 May; 27(4):738-742. PubMed ID: 28346240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study.
    Kim MK; Seong SJ; Park DC; Hong JH; Roh JW; Kang SB
    J Gynecol Oncol; 2020 Jul; 31(4):e51. PubMed ID: 32266800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with medroxyprogesterone acetate plus levonorgestrel-releasing intrauterine system for early-stage endometrial cancer in young women: single-arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2009).
    Kim MK; Seong SJ; Lee TS; Kim JW; Nam BH; Hong SR; Suh KS
    Jpn J Clin Oncol; 2012 Dec; 42(12):1215-8. PubMed ID: 23071290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conservative treatment with medroxyprogesterone acetate plus levonorgestrel intrauterine system for early-stage endometrial cancer in young women: pilot study.
    Kim MK; Yoon BS; Park H; Seong SJ; Chung HH; Kim JW; Kang SB
    Int J Gynecol Cancer; 2011 May; 21(4):673-7. PubMed ID: 21546871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System: A Korean Gynecologic-Oncology Group Study.
    Kim MK; Seong SJ; Kim JW; Jeon S; Choi HS; Lee IH; Lee JH; Ju W; Song ES; Park H; Ryu HS; Lee C; Kang SB
    Int J Gynecol Cancer; 2016 May; 26(4):711-5. PubMed ID: 26905333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
    Novikova OV; Nosov VB; Panov VA; Novikova EG; Krasnopolskaya KV; Andreeva YY; Shevchuk AS
    Gynecol Oncol; 2021 Apr; 161(1):152-159. PubMed ID: 33461741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of diagnostic accuracy between endometrial curettage and pipelle aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group Study (KGOG 2019).
    Kim MK; Seong SJ; Lee TS; Ki KD; Lim MC; Kim YH; Kim K; Joo WD
    Jpn J Clin Oncol; 2015 Oct; 45(10):980-2. PubMed ID: 26206899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continued medical treatment for persistent early endometrial cancer in young women.
    Cho A; Lee SW; Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT
    Gynecol Oncol; 2021 Feb; 160(2):413-417. PubMed ID: 33246662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women.
    Zhou H; Cao D; Yang J; Shen K; Lang J
    Int J Gynecol Cancer; 2017 Jul; 27(6):1178-1182. PubMed ID: 28562472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levonorgestrel-releasing intrauterine system versus oral medroxyprogesterone acetate in infertile women with endometrial hyperplasia without atypia.
    Campo G; Rebecchi A; Vanni VS; Pagliardini L; Patruno C; Papaleo E; Candiani M; Giardina P
    Reprod Biomed Online; 2021 Nov; 43(5):864-870. PubMed ID: 34629315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study.
    Leone Roberti Maggiore U; Martinelli F; Dondi G; Bogani G; Chiappa V; Evangelista MT; Liberale V; Ditto A; Ferrero S; Raspagliesi F
    J Gynecol Oncol; 2019 Jul; 30(4):e57. PubMed ID: 31074240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of high-dose progestin and long-term outcomes in young women with early-stage, well-differentiated endometrioid adenocarcinoma of uterine endometrium.
    Park H; Seok JM; Yoon BS; Seong SJ; Kim JY; Shim JY; Park CT
    Arch Gynecol Obstet; 2012 Feb; 285(2):473-8. PubMed ID: 21706284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.
    Ørbo A; Arnes M; Vereide AB; Straume B
    BJOG; 2016 Aug; 123(9):1512-9. PubMed ID: 26630538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Chin J; Konje JC; Hickey M
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma.
    Giannopoulos T; Butler-Manuel S; Tailor A
    Gynecol Oncol; 2004 Dec; 95(3):762-4. PubMed ID: 15582001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levonorgestrel-Releasing Intrauterine Systems Versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A Meta-Analysis.
    Yuk JS; Song JY; Lee JH; Park WI; Ahn HS; Kim HJ
    Ann Surg Oncol; 2017 May; 24(5):1322-1329. PubMed ID: 27896507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.